• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Arcus Biosciences, Inc. Common Stock (NY:RCUS)

    20.95 -0.40 (-1.87%)
    Streaming Delayed Price Updated: 12:41 PM EST, Jan 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Arcus Biosciences, Inc. Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    News headline image
    Arcus Outlines 2026 Plans for Casdatifan, its Potential Best-in-Class HIF-2a Inhibitor, and its Inflammation Programs
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Provides Update on Phase 3 STAR-221 Study and Concentrates Its R&D Investment on Casdatifan and Emerging Inflammation and Immunology Portfolio
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Participate in Two Upcoming Investor Conferences
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces Commencement of Public Offering of Common Stock
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Reports Third-Quarter 2025 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Taiho Pharmaceutical Exercises Option for an Exclusive License to Casdatifan in Japan and Certain Territories in Asia
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Anti-TIGIT Domvanalimab Plus Anti-PD-1 Zimberelimab and Chemotherapy Showed 26.7 Months of Median Overall Survival as First-Line Treatment of Unresectable or Advanced Gastroesophageal Adenocarcinomas in the Phase 2 EDGE-Gastric Study
    From Arcus Biosciences, Inc.
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Presents New Data for its HIF-2a Inhibitor Casdatifan and Discloses First Inflammation Programs at Investor Event
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Host Investor Event to Highlight its Late-Stage Casdatifan Program and Next Wave of Programs Focused on Inflammation
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Participate in Three Upcoming Investor Conferences
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences’ Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Reports First-Quarter 2025 Financial Results and Provides a Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Present First Combination Data for HIF-2a Inhibitor Casdatifan Plus Cabozantinib in an Oral Presentation at the 2025 ASCO Annual Meeting
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2025 Financial Results and Pipeline Update
    From Arcus Biosciences
    Via Business Wire
    News headline image
    Arcus Biosciences Announces New Employment Inducement Grants
    From Arcus Biosciences
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.